Answers are grounded in this paper and cite their sources.
Oxaliplatin-induced peripheral neuropathy (OIPN) is a major dose-limiting adverse reaction of chemotherapy. It is characterised by motor and sensory hypersensitivity, loss of myelinated nerve fibres, oxidative stress, mitochondrial dysfunction and neuroinflammation. Urolithin A, a bioactive gut metabolite of ellagitannins, is recognised for its ability to restore mitochondrial homeostasis. This study investigated the neuroprotective efficacy of urolithin A against experimental OIPN, focusing on its ability to simultaneously balance mitochondrial biogenesis and mitophagy. To study OIPN, male Sprague-Dawley rats were administered oxaliplatin (4 mg/kg) over a 4-week period, paired with concurrent oral doses of urolithin A (25 and 50 mg/kg). The animals were evaluated through behavioural assays (Von Frey, Hargreaves Plantar and Randall-Selitto, etc.) and functional tests measuring sensory and motor nerve conduction velocity. Oxidative stress markers (MDA and GSH) and mitochondrial dynamics, specifically biogenesis and mitophagy, were measured. In parallel, an in vitro study exposed Neuro2a cells to 50 μM of oxaliplatin, followed by urolithin A treatment (15 μM), to investigate its neuroprotective efficacy and underlying molecular mechanisms. Urolithin A significantly attenuated OIPN, alleviating thermal and mechanical hypersensitivity in behavioural assessments. It mitigated oxidative stress and mitochondrial dysfunction while promoting mitochondrial biogenesis via the SIRT1-mediated pathway both in vitro and in vivo. Simultaneously, urolithin A enhanced mitophagy by directly activating SIRT1-induced autophagy markers, leading to a marked reduction in inflammatory cytokine levels and eventual mitigation of neuropathic pain. Urolithin A protected against oxaliplatin-induced neurotoxicity in Neuro2a cells and reversed peripheral neuropathy in rats by restoring SIRT1-mediated mitochondrial biogenesis and mitophagy balance and maintaining mitochondrial health. These findings highlight urolithin A as a potential therapeutic candidate for OIPN.
No takes yet. Share an insight, caveat, or question.
Pal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: